View
3
Download
0
Category
Preview:
Citation preview
1 Projekt pn. "Rozwój i skalowanie innowacyjnego procesu wytwarzania terapeutycznego, rekombinowanego przeciwciała
monoklonalnego, w celu umożliwienia przemysłowego wdrożenia pierwszego polskiego leku biotechnologicznego do terapii onkologicznych oraz autoimmunologicznych" jest współfinansowany ze środków Europejskiego Funduszu Rozwoju
Regionalnego w ramach poddziałania 1.1.1 POIR na lata 2014-2020. .
Konstantynów Łódzki, date: 15.06.2018
MABION S. A. ul. Gen. Mariana Langiewicza 60 95-050 Konstantynów Łódzki Contact person's details: Patrycja Pietraszek e-mail: przetargi@mabion.eu phone no.: +48422077890
MODIFICATION ON 03.07.2018
THE DEADLINE FOR SUBMISSION OF OFFERS HAS BEEN EXTENDED TO THE
DATE 20.07.2018
REQUEST FOR TENDER
no. 2/06/2018/CD20
Project name: " Development and scaling up of an innovative production technology
of a therapeutic, recombinant monoclonal antibody, in order to launch commercial
manufacturing process of the first Polish biotechnological drug product for oncologic and
autoimmune therapies".
The procedure to select the best tender is conducted in observance of the rules of fair
competition, openness and transparency.
The provisions of the Act of 29 January 2004 Public Procurement Law do not apply to this
procedure.
I. PARTICULARS OF CONTRACTING ENTITY
MABION Spółka akcyjna with its registered office in Konstantynów Łódzki [95-050]
at Langiewicza 60, entered in the Business Register kept by the District Court for Łódź-
Śródmieście in Łódź, 20th Commercial Division of the National Court Register, under KRS
number: 0000340462, NIP: 7752561383, REGON: 100343056, with a share capital of PLN
1,372,077.20 [in words: one million three hundred seventy two thousand seventy seven
zlotys 20/100], fully paid up.
2 Projekt pn. "Rozwój i skalowanie innowacyjnego procesu wytwarzania terapeutycznego, rekombinowanego przeciwciała
monoklonalnego, w celu umożliwienia przemysłowego wdrożenia pierwszego polskiego leku biotechnologicznego do terapii onkologicznych oraz autoimmunologicznych" jest współfinansowany ze środków Europejskiego Funduszu Rozwoju
Regionalnego w ramach poddziałania 1.1.1 POIR na lata 2014-2020. .
II. OBJECT OF THE CONTRACT
1. Description of product
a. The aim of contract is successive supply of usage materials and regents. List
of materials and regents is presented in table below:
No Product Amount Unit
1.
Tryptic Soy Broth on 90 mm Petri dishes, optionally containing neutralizers, medium specification: storage temperature 15-25°C; closed dishes (screwed or click-safe closure); agar quantity of 25 ml min. per Petri dish; packed in three sleeves (without counting the packaging); validity of at least 6 months up to the production date; composition compliant with EP / USP; it is allowed to pack 100 items together
18000 dishes
2.
Tryptic Soy Broth on 55 mm Petri dishes (imprint plates), specification: storage temperature 15-25°C; closed dishes (screwed or click-safe closure); agar quantity of 25 ml min. per Petri dish; medium with neutralizers (lecithin, polysorbate 80, histidine, sodium thiosulphate), packed in three sleeves (without counting the packaging); a separating grid inside the plate; composition compliant with EP / USP’ it is allowed to pack 100 items together
17000 dishes
3.
Sabouraud medium with dextrose (4%) and agar (1.5%) on Petri dishes 90 mm, optionally containing neutralizers, medium specification: storage temperature 15-25 ° C; packaged in a minimum of two sleeves (not including the packaging); composition compliant with EP / USP; it is allowed to pack 20 items together
900 dishes
4.
Sabouraud medium R2A on Petri dishes 90 mm, specification: storage temperature 15-25 ° C; packaged in a minimum of two sleeves (not including the packaging); composition compliant with EP / USP
3600 dishes
5. THIO medium for sterility testing, specification: storage temperature 15-25 ° C; capacity 100 ml; packaging with septum; composition compliant with EP / USP
120 bottles
6. TSB medium for sterility testing, specification: storage temperature 15-25 ° C; capacity 100 ml; packaging with septum; composition compliant with EP / USP
120 bottles
7. Rinse A for sterility testing, specification: storage temperature 15-25 ° C; capacity 600 ml; packaging with septum; composition compliant with EP / USP
80 bottles
3 Projekt pn. "Rozwój i skalowanie innowacyjnego procesu wytwarzania terapeutycznego, rekombinowanego przeciwciała
monoklonalnego, w celu umożliwienia przemysłowego wdrożenia pierwszego polskiego leku biotechnologicznego do terapii onkologicznych oraz autoimmunologicznych" jest współfinansowany ze środków Europejskiego Funduszu Rozwoju
Regionalnego w ramach poddziałania 1.1.1 POIR na lata 2014-2020. .
8.
Viscose swabs with transport buffer, capacity 5 or 10 ml; swab adapted to take samples of environmental cleanliness, with transport liquid containing neutralisers of disinfectants, with the consistency of the fluid enabling the membrane filtration analysis. The Ordering Party requires that the swabs be at least double packed
4300 swabs
9. Plastic sterile heads, packed in a minimum of 2 sleeves (not including the packaging); adapted to the SAS super ISO device
2680 heads
10. Biochemical test for Bacillus identification with the reagents enabling the determination to be made
1120 strips
11. Biochemical test for cocci identification with the reagents enabling the determination to be made, it is allowed to pack 20 items together
1120 strips
12. Biochemical test for identification of gram negative, oxidase negative rods with the reagents enabling the determination to be made, it is allowed to pack 25 or 60 items together
760 strips
13. Biochemical test for identification of gram negative, oxidase positive rods with the reagents enabling the determination to be made, it is allowed to pack 25 or 24 test items together
220 strips
14. Biochemical test for yeasts identification with the reagents enabling the determination to be made
80 strips
15a. Set of reagents for gram staining (crystal violet, Lugol's liquid, alkaline fuchsin, acetone) in bottles with dispenser capacity of each reagent 100 ml or
40
set
(a set of four bottles
of reagents)
15b. Set of reagents for gram staining (crystal violet, Lugol's liquid, alkaline fuchsin, acetone) in bottles with dispenser capacity of each reagent 200 ml or
20
Set
(a set of four bottles
of reagents)
15c. Set of reagents for gram staining (crystal violet, Lugol's liquid, alkaline fuchsin, acetone) in bottles with dispenser capacity of each reagent 250 ml
16
Set
(a set of four bottles
of reagents)
16.
Sodium chloride with peptone for microbiology with composition potassium dihydrogen phosphate 3,6g/l; disodium hydrogen phosphate dihydrate 7,2 g/l; sodium chloride 4,3g/l; peptone from meat 1,0g/l) a package capacity of 500 g is allowed
20000 g
17. Oxidase detection strips it is allowed to pack 50 items together 3600 strips
4 Projekt pn. "Rozwój i skalowanie innowacyjnego procesu wytwarzania terapeutycznego, rekombinowanego przeciwciała
monoklonalnego, w celu umożliwienia przemysłowego wdrożenia pierwszego polskiego leku biotechnologicznego do terapii onkologicznych oraz autoimmunologicznych" jest współfinansowany ze środków Europejskiego Funduszu Rozwoju
Regionalnego w ramach poddziałania 1.1.1 POIR na lata 2014-2020. .
18.
Filter units consisting of 100 ml sterile funnel and 47 mm filter with 0.45 μm pore size (white filters made of cellulose extracts (MCE)) compatible with EZ Stream Pump and EZ FIT Mainfold handle
4500 funnels
b. Material supply shall result from each order previously submitted by the Ordering
Party. Total pool of materials presented in the chart will be split into regular
deliveries, according to the schedule below.
No
materials/
regents
Total
amount
Quarter number
III
(2018)
IV
(2018)
I
(2019)
II
(2019)
III
(2019)
IV
(2019)
1. 18000 4740 4740 2130 2130 2130 2130
2. 17000 4440 4440 2030 2030 2030 2030
3. 900 150 150 150 150 150 150
4. 3600 600 600 600 600 600 600
5. 120 20 20 20 20 20 20
6. 120 20 20 20 20 20 20
7. 80 14 14 14 14 14 10
8. 4300 1000 900 600 600 600 600
9. 2680 640 640 320 360 360 360
10. 1120 200 200 180 180 180 180
11. 1120 200 200 180 180 180 180
12. 760 140 140 120 120 120 120
13. 220 40 40 40 40 30 30
14. 80 ND 20 20 20 20 ND
5 Projekt pn. "Rozwój i skalowanie innowacyjnego procesu wytwarzania terapeutycznego, rekombinowanego przeciwciała
monoklonalnego, w celu umożliwienia przemysłowego wdrożenia pierwszego polskiego leku biotechnologicznego do terapii onkologicznych oraz autoimmunologicznych" jest współfinansowany ze środków Europejskiego Funduszu Rozwoju
Regionalnego w ramach poddziałania 1.1.1 POIR na lata 2014-2020. .
15a. 40 8 8 6 6 6 6
15b. 20 4 4 3 3 3 3
16. 20000 5000 5000 3000 2000 2000 3000
17. 3600 600 600 600 600 600 600
18. 4500 900 900 600 600 750 750
c. The Ordering Party permits for derogations from the schedule while keeping the total
amount of material/ reagent being the subject of the tender procedure. .
d. Materials shall be protected with a package, which guarantees a possibility to deliver
and store them with no risk of damage or their quality worsening.
2. Common Procurement Vocabulary (CPV): 33696500-0: Laboratory regents;
3. The time of offer validity period – 90 days;
4. Validity of the contract – from the date of conclusion by 31.12.2019;
5. Place of realization of order: Konstantynów Łódzki.
III. FORMAL REQUIREMENTS FOR TENDERS
1. Each tenderer may submit only one tender.
2. Tenderer must submit an offer using the template attached as Annex 1, the list
of parameters for the device template enclosure in Annex 2 and the conditions of free
warranty service template enclosure in Annex 5 to the present Request for Tender. The
offer should be accompanied by a statement on the lack of personal or capital links,
constituting an Annex 3 and a declaration on the fulfillment of the formal conditions
of participation in the procedure constituting Appendix 4 to this Offer Request. The
contractor forbids any modification of the contents of the documents, except for places
to fill the content of the offer or statements.
6 Projekt pn. "Rozwój i skalowanie innowacyjnego procesu wytwarzania terapeutycznego, rekombinowanego przeciwciała
monoklonalnego, w celu umożliwienia przemysłowego wdrożenia pierwszego polskiego leku biotechnologicznego do terapii onkologicznych oraz autoimmunologicznych" jest współfinansowany ze środków Europejskiego Funduszu Rozwoju
Regionalnego w ramach poddziałania 1.1.1 POIR na lata 2014-2020. .
3. The Contracting Entity calls the Tenderers who did not submit required statements
or who submitted the aforementioned statements and documents, containing errors
or incomplete or that raise Contracting Entity’s doubts as to its submission, completion
or correction them within the 3 working days as indicated in point VII. 1, or to give
explanations, unless the submitted tender would be subject to rejection or the whole
proceeding is to be declare void. If the Tenderer fails to submit the tender
or to complete or correct the aforementioned statements or documents within the
period predescribed, its tender shall be rejected.
4. The tender must include:
a. full name of the tenderer or tenderers (if they submit the tender jointly);
b. Tenderer's address or registered office, NIP number [or equivalent tax identification
number];
c. name, phone number and e-mail of the contact person who handles the tender;
d. the overall price for the tender proposed by Tenderer, given in PLN or EUR, filled
in using digits and words [the price should be stated inclusive of the tax
on goods and services (VAT) unless the tender is submitted by a foreign entity which
is not required to pay VAT in Poland on the basis of separate provisions. Tenders
submitted by such Tenderers should state the price net of VAT]. In the event that the
tender contains an ambiguity in relation to the tender sum, the amount in words shall
prevail.
e. The unit prices for individual materials given in PLN or EUR, filled in using digits [the
price should be stated inclusive of the tax on goods and services (VAT) unless the
tender is submitted by a foreign entity which is not required to pay VAT in Poland
on the basis of separate provisions. Tenders submitted by such Tenderers should
state the price net of VAT]. In the event that the tender contains an ambiguity
in relation to the tender sum, the amount in words shall prevail.
f. Time of processing the order which was submitted according to the schedule –
deadline, before which the order shall be delivered to the Ordering Party – shall not
7 Projekt pn. "Rozwój i skalowanie innowacyjnego procesu wytwarzania terapeutycznego, rekombinowanego przeciwciała
monoklonalnego, w celu umożliwienia przemysłowego wdrożenia pierwszego polskiego leku biotechnologicznego do terapii onkologicznych oraz autoimmunologicznych" jest współfinansowany ze środków Europejskiego Funduszu Rozwoju
Regionalnego w ramach poddziałania 1.1.1 POIR na lata 2014-2020. .
be longer than 5 working days from the moment of submitting a single order by the
Ordering Party in case of an order submitted according to the schedule. Working days
shall be understood as days from Monday till Friday, with the exceptions of public
holidays.
g. The Ordering Party allows for the possibility of submitting orders in dates other than
indicated in point II.1.b. In such cases, time of processing the order submitted
as a derogation from the schedule – deadline, before which the order may
be delivered to the Ordering Party – shall not be longer than 10 working days from
the moment of submitting a single order by the Ordering Party in case of an order
submitted independently from the schedule (refers to point 1c). Working days shall
be understood as days from Monday till Friday, with the exceptions of public
holidays.
h. Conditions of material delivery – during each transport of materials no. 1-7 and 10-14
defined in the tender procedure, it is required to control temperature with the use
of a calibrated temperature recorder. The rest of materials require a statement of the
Tenderer that transport temperature does not influence the quality of materials.
5. Costs of materials delivery are covered by the Tenderer.
6. The tender shall contain an attached folder (advertising, propaganda, informative
leaflet, usually with descriptions, photos, maps or data concerning offered products
or services) or a brochure (propaganda article or essay, published as a separate
publication) for the offered material, which – with the description of the object of order
– confirms the requirements set out by the Ordering Party.
7. The offer and all attachments should be signed by an authorized representative of the
Tenderer. All changes to the text of the tender must be initialed by the person who signs
the Tender.
8. The offer, together with the accompanying documents, should be prepared in Polish
or in English language.
8 Projekt pn. "Rozwój i skalowanie innowacyjnego procesu wytwarzania terapeutycznego, rekombinowanego przeciwciała
monoklonalnego, w celu umożliwienia przemysłowego wdrożenia pierwszego polskiego leku biotechnologicznego do terapii onkologicznych oraz autoimmunologicznych" jest współfinansowany ze środków Europejskiego Funduszu Rozwoju
Regionalnego w ramach poddziałania 1.1.1 POIR na lata 2014-2020. .
9. The Ordering Party allows for submission of partial tenders. Tenders shall be submitted
for the entire item indicated in the subject of the order. It is not allowed to submit
tenders for delivery of a part of materials or reagents indicated in a given item.
10. Contracting Entity doesn’t accept variant offers.
11. During the tender procedure, only materials and reagents meeting requirements
of specification provided in the subject of the order will be considered.
12. Tender that not satisfy the requirements referred to in the points 1, 5, 9, 10 shall
be subject to rejection, in the points 2, 4, 6-8,11 shall be subject to complement.
IV. FORMAL REQUIREMENTS FOR PARTICIPATION IN THE PROCEDURE
A tender may be submitted by any entity that has appropriate knowledge and experience
which enable it to perform the contract in accordance with the highest standards and whose
financial situation ensures that the contract will be performed in full.
In order to confirm the fulfilment of the above mentioned conditions the Tenderer is obliged
to provide, together with the offer a Declaration stated on the Annex no. 4. Tenderer who
fails to comply with any of the requirements mentioned will be excluded
from the proceedings.
V. EXCLUSIONS
1. To avoid a conflict of interest, public contracts may not be awarded to any entities that
have personal or capital links with Contracting Entity. Capital or personal links are
understood as mutual ties between Contracting Entity or persons authorised
to bind Contracting Entity or persons who act on behalf of Contracting Entity
in connection with preparing and conducting the procedure for selection
of a contractor, and the contractor, which are in particular the following:
a. participation in a partnership as a partner of a civil law partnership or general
partnership;
9 Projekt pn. "Rozwój i skalowanie innowacyjnego procesu wytwarzania terapeutycznego, rekombinowanego przeciwciała
monoklonalnego, w celu umożliwienia przemysłowego wdrożenia pierwszego polskiego leku biotechnologicznego do terapii onkologicznych oraz autoimmunologicznych" jest współfinansowany ze środków Europejskiego Funduszu Rozwoju
Regionalnego w ramach poddziałania 1.1.1 POIR na lata 2014-2020. .
b. holding a least 10% of shares;
c. serving as a member of a supervisory body or a managing body, acting as a registered
representative (prokurent) or an attorney;
d. being a spouse, a relative by lineal consanguinity or affinity, by collateral consanguinity
to the 2nd degree or affinity to the 2nd degree, or a person linked by way of adoption,
custody or legal guardianship;
2. Tenderer is required to submit, along with its tender, a statement attached
as Annex 3 to this Request for Tender.
VI. EVALUATION CRITERIA FOR SELECTION OF TENDER
1. When selecting the best Tenderer, Contracting Entity will take into consideration the
following criteria:
L.p. Name Maximal score Weight [%]
1. Net price 100 55
2. Delivery time accordance with the schedule
100 20
3. Delivery time out of schedule 100 25
TOTAL 300 100
The evaluation among groups of products of the Tenderers who have completed
requirements will be made on the basis of following criteria:
1. Net price (“P”) – 100 point (weight of criteria 65%)
Purchaser in the calculation of this criterion will take into account net price of 1 piece in PLN
for a given materials or regents. If price is in EUR, the Offer will be taken into consideration
after price calculation according to NBP exchange rate with of on the opening day of the
offers.
10 Projekt pn. "Rozwój i skalowanie innowacyjnego procesu wytwarzania terapeutycznego, rekombinowanego przeciwciała
monoklonalnego, w celu umożliwienia przemysłowego wdrożenia pierwszego polskiego leku biotechnologicznego do terapii onkologicznych oraz autoimmunologicznych" jest współfinansowany ze środków Europejskiego Funduszu Rozwoju
Regionalnego w ramach poddziałania 1.1.1 POIR na lata 2014-2020. .
Offer with the lowest price will receive 100 points multiplied by the weight of criterion and
will be adopted as the basis for the study of other offers. The price of the next offer will
be evaluated according to the following formula:
𝐶𝑟𝑖𝑡𝑒𝑟𝑖𝑜𝑛 C = 𝑇ℎ𝑒 𝑙𝑜𝑤𝑒𝑠𝑡 𝑜𝑓𝑓𝑒𝑟𝑒𝑑 𝑝𝑟𝑖𝑐𝑒 (𝑛𝑒𝑡𝑡𝑜 𝑝𝑒𝑟 𝑝𝑖𝑒𝑐𝑒)
𝑂𝑓𝑓𝑒𝑟𝑒𝑑 𝑝𝑟𝑖𝑐𝑒 (𝑛𝑒𝑡𝑡𝑜 𝑝𝑒𝑟 𝑝𝑖𝑒𝑐𝑒)∗ 100 𝑝𝑘𝑡
∗ 65% (𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑐𝑟𝑖𝑡𝑒𝑟𝑖𝑜𝑛)
2. Delivery time accordance with the schedule – Term “TH” - 100 point (weight
of criteria 20%)
Offer with the shortest execution time in accordance with the schedule (counted in working
days) will receive 100 points and will be on the first place in ranking. If execution time
is presented as a period of time, to evaluate this criteria, Purchaser will take into account the
longest date. Offers with the maximum execution time settled by Purchaser (5 days) will
receive 0 points in this criterion. Every offer providing longer term placing in next position
in ranking of this criterion will receive -10 points (minus 10) less than its predecessor (second
Offer will receive 90 points, third 80 points etc).
The method of calculating the number of points:
Criterion “T” = number of points x 20% (weight of criterion)
3. Delivery time accordance with the schedule – Term “TH” - 100 point (weight
of criteria 25%)
Offer with the shortest execution time out of schedule (counted in working days) will receive
100 points and will be on the first place in ranking. If execution time is presented as a period
of time, to evaluate this criteria, Purchaser will take into account the longest date. Offers
with the maximum execution time settled by Purchaser (10 days) will receive 0 points in this
criterion. Every offer providing longer term placing in next position in ranking of this
criterion will receive -10 points (minus 10) less than its predecessor (second Offer will
receive 90 points, third 80 points etc).
11 Projekt pn. "Rozwój i skalowanie innowacyjnego procesu wytwarzania terapeutycznego, rekombinowanego przeciwciała
monoklonalnego, w celu umożliwienia przemysłowego wdrożenia pierwszego polskiego leku biotechnologicznego do terapii onkologicznych oraz autoimmunologicznych" jest współfinansowany ze środków Europejskiego Funduszu Rozwoju
Regionalnego w ramach poddziałania 1.1.1 POIR na lata 2014-2020. .
The method of calculating the number of points:
Criterion “T” = number of points x 25% (weight of criterion
Final score will be evaluated by summing all of received points by Offer according
to equation:
Score = Criterion “P” + Criterion “TH” + Criterion “TPH”
1. Purchaser will select the most advantageous tender, which obtains the highest number
of total points.
2. In the case that, during the purchase, the Purchaser will decide between several offers
with equal number of points, the most favorable offer for environmental and climate
impact will be chosen. For this purpose, the Ordering Party has the right to call on the
Tenderers who have received the highest number of points to complete the offer
by giving the information indicated by the Ordering Party regarding the impact of the
object of the offer on the environment.
3. If all tenders contained the price higher than the amount of the money which
Contracting Entity can spend, to finance the contract, Contracting Entetity provides the
ability to negotiate prices with Tenderers.
4. Contracting Entity reserves the right to request from Tenderers some additional
information which it deems necessary to properly evaluate the submitted tenders.
5. Contracting Entity reserves the right to decide that no award will be made in the
procedure and no tender will be selected.
6. Contracting Entity reserves the right to change the announcement or terms of the
inquiry or revocation or proceeding for any reason.
7. Contracting Entity reserves the right to place orders exceeding the number of packages
specified in the table.
12 Projekt pn. "Rozwój i skalowanie innowacyjnego procesu wytwarzania terapeutycznego, rekombinowanego przeciwciała
monoklonalnego, w celu umożliwienia przemysłowego wdrożenia pierwszego polskiego leku biotechnologicznego do terapii onkologicznych oraz autoimmunologicznych" jest współfinansowany ze środków Europejskiego Funduszu Rozwoju
Regionalnego w ramach poddziałania 1.1.1 POIR na lata 2014-2020. .
VII. PLACE, MANNER AND DEADLINE FOR SUBMITTING TENDERS
1. The tender should be delivered in writing by mail, courier service or personally at the
address of Contracting Entity given in Section I of this Request for Tender or send
by e- mail at the following e-mail address: przetargi@mabion.eu by 20.07.2018 the
tender should be received by Contracting Entity. The date of the offer will be the date
of delivery to the Purchaser.
2. The tender should be placed inside a non-transparent and sealed envelope which must
bear the following address details of Tenderer, its name and the following text: "Tender
regarding Request for Tender no. 2/06/2018/CD20 – not to be opened before
23.07.2018 at 09.00 am.” If you submit an offer by an e-mail, the above mentioned text
should be included in the message tittle.
3. The offers will open 23.07.2018 at 9.00 am.
4. Tenders submitted after the deadline will not be considered.
5. The Contracting Entity informs that in accordance with the guidelines on the eligibility
of expenditures under the European Regional Development Fund, European Social Fund
and the Cohesion Fund for the period 2014-2020, the Contracting Entity at the request
of the Tenderer who submitted the tender is obligated to make available to the Tenderer
protocol of tender proceedings, with the exception of parts of tenders which constitutes
the company’s secret within the meaning of the provisions of the Act of 16 April 1993
on Combating Unfair Competition (Dz. U. of 2003 No. 169, item 1650, with amendments).
6. The Contracting Entity recommends to submit the proprietary information which
constitutes the company’s secret in a separate inner envelope marked “company’s
secret” or to bound it (staple) separately from the other public documents. The lack
of a clear indication that the information constitutes a company's secret means that all
the statements made in the course of the present proceedings are open to the public
without any reservation. Request for confidentiality of the information which are not
company’s secrets within the meaning of the Act on Combating Unfair Competition, will
be treated as ineffective and will result its declassification.
13 Projekt pn. "Rozwój i skalowanie innowacyjnego procesu wytwarzania terapeutycznego, rekombinowanego przeciwciała
monoklonalnego, w celu umożliwienia przemysłowego wdrożenia pierwszego polskiego leku biotechnologicznego do terapii onkologicznych oraz autoimmunologicznych" jest współfinansowany ze środków Europejskiego Funduszu Rozwoju
Regionalnego w ramach poddziałania 1.1.1 POIR na lata 2014-2020. .
7. Tenderer may change, complete or withdraw the tender before the deadline for
submission of the tenders. In the event of correction, completion or withdraw of the
tender, the above mentioned point 2 shall apply accordingly, but with the annotation
on the envelope, respectively: CHANGE/COMPLETION/TENDER WITHDRAW.
8. A decision following a comparison of tenders is final, that is, the results of the tender
procedure conducted by the Contracting Entity cannot be challenged.
VIII. WEBSITE WITH NOTICE OF THE REQUEST FOR TENDER
https://mabion.eu/pl/2/o-mabion/zapytania-ofertowe/
https://bazakonkurencyjnosci.gov.pl/
IX. ADDITIONAL INFORMATION
Additional information on behalf of the Ordering Party is provided by:
Patrycja Pietraszek przetargi@mabion.eu
X. CONTRACT AMENDEMENTS CONDITIONS
The Contracting Entity stipulates the following conditions that may cause necessity
to amend the contract in comparison to the content of the submitted tender, unless they
lead to a change in the nature of the contract:
a) change of time for performance of the subject of the contract due
to circumstances beyond the control of the awarded tenderer;
b) remuneration stipulated in the contract may be changed due to change in the
applicable VAT rate;
c) amendments to general applicable law that may affect performance of the subject
of the contract;
d) Necessity of changing the agreement is caused by conditions which the Contracting
Party – performing its responsibilities with the utmost care – could not predict and
the value of the change is not higher than 50% of the value
14 Projekt pn. "Rozwój i skalowanie innowacyjnego procesu wytwarzania terapeutycznego, rekombinowanego przeciwciała
monoklonalnego, w celu umożliwienia przemysłowego wdrożenia pierwszego polskiego leku biotechnologicznego do terapii onkologicznych oraz autoimmunologicznych" jest współfinansowany ze środków Europejskiego Funduszu Rozwoju
Regionalnego w ramach poddziałania 1.1.1 POIR na lata 2014-2020. .
of the order originally stated in the agreement
e) total value of changes is less than 209 000 EUR and simultaneously less than
10% of the value of the order that was originally stated in the agreement
f) change of obvious typographical and arithmetical errors.
XI. ATTACHMENTS
Attached to the Request for Tender is the tender form [Annex 1], the statement on the
absence of personal or capital links [Annex 2], the statement on the fulfillment of the formal
conditions for participation in the procedure [Annex 3]
______________________
signature of Contracting Entity
15 Projekt pn. "Rozwój i skalowanie innowacyjnego procesu wytwarzania terapeutycznego, rekombinowanego przeciwciała
monoklonalnego, w celu umożliwienia przemysłowego wdrożenia pierwszego polskiego leku biotechnologicznego do terapii onkologicznych oraz autoimmunologicznych" jest współfinansowany ze środków Europejskiego Funduszu Rozwoju
Regionalnego w ramach poddziałania 1.1.1 POIR na lata 2014-2020. .
ANNEX 1 – to Request for Tender no. 2/06/2018/CD20 dated 15.06.2018
FORM OF TENDER
(template)
I. Name and address of tenderer and its registration details, including NIP (tax ID): ………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………………
II. Name, phone number and e-mail of the contact person:
………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………………
III. Unit price for individual materials: *Incuded in the scoring criterion
Material/
Regent Net price per 1 piece* Gross price per 1 piece*
Delivery time TH* Delivery time TPH*
Tryptic Soy Broth on 90 mm Petri dishes
……………………………………….
[in words: ……………………….]
……………………………………….
[in words: ……………………….]
…………………………. days from the date of order delivery
…………………………. days from the date of order delivery
Tryptic Soy Broth on 55 mm Petri dishes
……………………………………….
[in words:……………………….]
……………………………………….
[in words: ……………………….]
…………………………. days from the date of order delivery
…………………………. days from the date of order delivery
Sabouraud medium with dextrose (4%) and agar (1.5%) on Petri dishes 90 mm
……………………………………….
[in words:……………………….]
……………………………………….
[in words: ……………………….]
…………………………. days from the date of order delivery
…………………………. days from the date of order delivery
Sabouraud medium R2A on Petri dishes 90 mm
……………………………………….
In words: ……………………….]
……………………………………….
[in words: ……………………….]
…………………………. days from the date of order delivery
…………………………. days from the date of order delivery
THIO medium for sterility testing
……………………………………….
[in words:……………………….]
……………………………………….
[in words: ……………………….]
…………………………. days from the date of order delivery
…………………………. days from the date of order delivery
16 Projekt pn. "Rozwój i skalowanie innowacyjnego procesu wytwarzania terapeutycznego, rekombinowanego przeciwciała
monoklonalnego, w celu umożliwienia przemysłowego wdrożenia pierwszego polskiego leku biotechnologicznego do terapii onkologicznych oraz autoimmunologicznych" jest współfinansowany ze środków Europejskiego Funduszu Rozwoju
Regionalnego w ramach poddziałania 1.1.1 POIR na lata 2014-2020. .
TSB medium for sterility testing
……………………………………….
[in words:……………………….]
……………………………………….
[in words: ……………………….]
…………………………. days from the date of order delivery
…………………………. days from the date of order delivery
Rinse A for sterility testing
……………………………………….
[in words:……………………….]
……………………………………….
[in words: ……………………….]
…………………………. days from the date of order delivery
…………………………. days from the date of order delivery
Viscose swabs with transport buffer, capacity 5 or 10 ml
…………………………………….
in words: ……………………….]
……………………………………….
[in words: ……………………….]
…………………………. days from the date of order delivery
…………………………. days from the date of order delivery
Plastic sterile heads, ……………………………………….
[in words:……………………….]
……………………………………….
[in words: ……………………….]
…………………………. days from the date of order delivery
…………………………. days from the date of order delivery
Biochemical test for Bacillus identification
……………………………………….
[in words:……………………….]
……………………………………….
[in words: ……………………….]
…………………………. days from the date of order delivery
…………………………. days from the date of order delivery
Biochemical test for cocci identification
……………………………………….
[in words:……………………….]
……………………………………….
[in words: ……………………….]
…………………………. days from the date of order delivery
…………………………. days from the date of order delivery
Biochemical test for identification of gram negative, oxidase negative rods
……………………………………….
[in words:……………………….]
……………………………………….
[in words: ……………………….]
…………………………. days from the date of order delivery
…………………………. days from the date of order delivery
Biochemical test for identification of gram negative, oxidase positive rods
……………………………………….
[in words:……………………….]
……………………………………….
[in words: ……………………….]
…………………………. days from the date of order delivery
…………………………. days from the date of order delivery
Biochemical test for yeasts identification
……………………………………….
[in words:……………………….]
……………………………………….
[in words: ……………………….]
…………………………. days from the date of order delivery
…………………………. days from the date of order delivery
Set of reagents for gram staining in bottles with dispenser capacity of each reagent 100 ml
……………………………………….
[in words:……………………….]
……………………………………….
[in words: ……………………….]
…………………………. days from the date of order delivery
…………………………. days from the date of order delivery
17 Projekt pn. "Rozwój i skalowanie innowacyjnego procesu wytwarzania terapeutycznego, rekombinowanego przeciwciała
monoklonalnego, w celu umożliwienia przemysłowego wdrożenia pierwszego polskiego leku biotechnologicznego do terapii onkologicznych oraz autoimmunologicznych" jest współfinansowany ze środków Europejskiego Funduszu Rozwoju
Regionalnego w ramach poddziałania 1.1.1 POIR na lata 2014-2020. .
Set of reagents for gram staining in bottles with dispenser capacity of each reagent 200 ml
……………………………………….
[in words:……………………….]
……………………………………….
[in words: ……………………….]
…………………………. days from the date of order delivery
…………………………. days from the date of order delivery
Set of reagents for gram staining in bottles with dispenser capacity of each reagent 250 ml
……………………………………….
[in words:……………………….]
……………………………………….
[in words: ……………………….]
…………………………. days from the date of order delivery
…………………………. days from the date of order delivery
Sodium chloride with peptone for microbiology
……………………………………….
[in words:……………………….]
……………………………………….
[in words ……………………….]
…………………………. days from the date of order delivery
…………………………. days from the date of order delivery
Oxidase detection strips
……………………………………….
[in words:……………………….]
……………………………………….
[in words: ……………………….]
…………………………. days from the date of order delivery
…………………………. days from the date of order delivery
Filter units ……………………………………….
[in words:……………………….]
……………………………………….
[in words: ……………………….]
…………………………. days from the date of order delivery
…………………………. days from the date of order delivery
IV. Value of the tender a. Net price:…………………………. [in words: …………………………] b. Gross price:………………………..[in words: ………………………..]
V. Date of payment:
………………………..days from the date of delivery of the invoice to the Purchaser (min 30 days)
VI. Declaration of the Tenderer about the company’s secret (if applicable):
I /we declare that:
1. The following information are company’s secret (if applicable)*:
………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………
*(the Tenderer shall indicate documents containing the company’s secret)
18 Projekt pn. "Rozwój i skalowanie innowacyjnego procesu wytwarzania terapeutycznego, rekombinowanego przeciwciała
monoklonalnego, w celu umożliwienia przemysłowego wdrożenia pierwszego polskiego leku biotechnologicznego do terapii onkologicznych oraz autoimmunologicznych" jest współfinansowany ze środków Europejskiego Funduszu Rozwoju
Regionalnego w ramach poddziałania 1.1.1 POIR na lata 2014-2020. .
2. Explanation of the request for confidentiality of the aforementioned information
I/we enclose as attachment to the tender.
VII. Other statements by the Tenderer:
I declare, that:
- I am bound by this offer for a period of 90 days from the deadline of submission
of offers
- I accept to cover the cost of delivery
Place and date: ………………………..
…..………………………………………………………………….…..
Signature of Tenderer or Tenderer's authorised representative
and company seal (if Tenderer is an entity that runs business activity)
19 Projekt pn. "Rozwój i skalowanie innowacyjnego procesu wytwarzania terapeutycznego, rekombinowanego przeciwciała
monoklonalnego, w celu umożliwienia przemysłowego wdrożenia pierwszego polskiego leku biotechnologicznego do terapii onkologicznych oraz autoimmunologicznych" jest współfinansowany ze środków Europejskiego Funduszu Rozwoju
Regionalnego w ramach poddziałania 1.1.1 POIR na lata 2014-2020. .
ANNEX 2 – to Request for Tender no. 2/06/2018/CD20 dated 15.06.2018
STATEMENT ON THE ABSENCE OF PERSONAL OR CAPITAL LINKS
I, the undersigned …………………………………………………………………………………………………………….....,
[name and surname of Tenderer or its authorised representative], declare that
…………………………………. [name of tenderer] has / I have no personal or capital links with
Contracting Entity.
Capital or personal links are understood as mutual ties between Contracting Entity
or persons authorised to bind Contracting Entity or persons who act on behalf of Contracting
Entity in connection with preparing and conducting the procedure for selection
of a contractor, and the contractor, which are in particular the following:
a. participation in a partnership as a partner of a civil law partnership or general
partnership,
b. holding a least 10% of shares,
c. serving as a member of a supervisory body or a managing body, acting as a registered
representative (prokurent) or an attorney,
d. being a spouse, a relative by lineal consanguinity or affinity, by collateral
consanguinity to the 2nd degree or affinity to the 2nd degree, or a person linked by
way
of adoption, custody or legal guardianship.
Place and date: …………………
…..………………………………………………………………….…..
Signature of Tenderer or Tenderer's authorised representative
and company seal (if Tenderer is an entity that runs business activity
20 Projekt pn. "Rozwój i skalowanie innowacyjnego procesu wytwarzania terapeutycznego, rekombinowanego przeciwciała
monoklonalnego, w celu umożliwienia przemysłowego wdrożenia pierwszego polskiego leku biotechnologicznego do terapii onkologicznych oraz autoimmunologicznych" jest współfinansowany ze środków Europejskiego Funduszu Rozwoju
Regionalnego w ramach poddziałania 1.1.1 POIR na lata 2014-2020. .
ANNEX 3 – to Request for Tender no. 2/06/2018/CD20 dated 15.06.2018
STATEMENT ON FULFILLING THE FORMAL REQUIREMENTS FOR PARTICIPATION IN THE PROCEDURE
I, the undersigned …………………………………………………………………………………………………………….....,
[name and surname of Tenderer or its authorised representative], declare that
…………………………………. [name of tenderer]
1) have/ has the appropriate knowledge and experience to perform the contract
in the highest standards
2) have/ has a financial situation that guarantees the performance of the whole order
Place and date: ………………………..
…..………………………………………………………………….…..
Signature of Tenderer or Tenderer's authorised representative
and company seal (if Tenderer is an entity that runs business activity)
Recommended